BioSpace News Archive

The designation will provide for an expedited pathway for regulatory review of the preventative medication, which could come later this year.

Itolizumab is a first-in-class monoclonal antibody that selectively targets the CD6-ALCAM pathway.

In general, studies have shown that people with Type O blood appear to be more protected than those with Type A, who are seemingly more vulnerable, according to NBC News.

Although the trial failed to meet the primary endpoint of PFS, the data for overall survival as a co-primary endpoint is not yet mature. The company plans to continue the trial until the next planned analysis.

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 13, 2020.

Boston-based Dewpoint Therapeutics and Merck will collaborate to develop a novel mechanism for the treatment of HIV by harnessing Dewpoint’s proprietary platform for condensate-based drug discovery.

Angelman Syndrome is a genetic disorder that mostly affects the nervous system.

The COVID-19 pandemic underscored weaknesses in critical industries in the U.S. In the pharmaceutical industry, the global nature of the business, long considered a benefit, became not just a weakness but a national security threat.

Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the closing of its previously announced underwritten public offering of 17,275,000 shares of its common stock, which includes the underwriters’ full exercise of their option to purchase additional shares and pre-funded

Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics™) and Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced a collaboration to detect neuregulin 1 (NRG1) fusions in cancer patients.